Ravulizumab (Ultomiris) accepted for restricted use within NHS Scotland for treatment of paroxysmal nocturnal haemoglobinuria

Treatment is restricted patients with haemolysis with clinical symptom(s) indicative of high disease activity and/or patients who are clinically stable after having been treated with eculizumab for at least the past six months.

Source:

Scottish Medicines Consortium